Stock analysts at StockNews.com initiated coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY – Get Free Report) in a research note issued on Tuesday. The firm set a “sell” rating on the stock.
NovaBay Pharmaceuticals Price Performance
NYSE:NBY opened at $0.08 on Tuesday. NovaBay Pharmaceuticals has a one year low of $0.07 and a one year high of $1.42. The company’s 50-day simple moving average is $0.12 and its 200 day simple moving average is $0.21. The firm has a market capitalization of $2.79 million, a P/E ratio of -0.02 and a beta of 1.97.
NovaBay Pharmaceuticals (NYSE:NBY – Get Free Report) last released its quarterly earnings data on Tuesday, March 26th. The company reported ($0.95) earnings per share for the quarter. NovaBay Pharmaceuticals had a negative net margin of 65.46% and a negative return on equity of 150.14%. The company had revenue of $3.73 million for the quarter. On average, equities research analysts expect that NovaBay Pharmaceuticals will post -0.41 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
NovaBay Pharmaceuticals Company Profile
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.
See Also
- Five stocks we like better than NovaBay Pharmaceuticals
- What Investors Need to Know to Beat the Market
- High-Yield Texas Instruments Could Hit New Highs Soon
- Comparing and Trading High PE Ratio Stocks
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- What Are the U.K. Market Holidays? How to Invest and Trade
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.